Abstract
Human papillomavirus (HPV) is the well-known second most cause of cervical cancer in women worldwide. According to the WHO survey, 70% of the total cervical cancers are associated with types HPV 16 and 18. Presently used prophylactic vaccine for HPV contains mainly capsid protein of L1 virus like particles (VLPs). Correct folding of VLPs and display of neutralizing epitopes are the major constraint for VLP-based vaccines. Further, monoclonal antibodies (mAbs) play a vital role in developing therapeutics and diagnostics. mAbs are also useful for the demonstration of VLP conformation, virus typing and product process assessment as well. In the present study, we have explored the usefulness of mAbs generated against sf-9 expressed HPV 16 VLPs demonstrated as type-specific and conformational dependent against HPV 16 VLPs by ELISA. High affinity and high pseudovirion neutralization titer of mAbs indicated their potential for the development of prophylactic vaccines for HPV. Also, the type-specific and conformational reactivity of the mAbs to HPV 16 VLPs in sf-9 cells by immunofluorescence assay proved their diagnostic potential.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. P.K. Goon M.A. Stanley J. Ebmeyer L. Steinsträsser T. Upile W. Jerjes M. Bernal-Sprekelsen M. Görner H.H. Sudhoff 2009 HPV & head and neck cancer: a descriptive update Head Neck Oncol 1 36.
-
2. N. Munoz F.X. Bosch S. de Sanjose R. Herrero X. Castellsague K.V. Shah P.J. Snijders C.J. Meijer 2003 Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518 527.
-
3. J.S. Smith L. Lindsay B. Hoots J. Keys S. Franceschi R. Winer G.M. Clifford 2007 Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Int J Cancer 121 621 632.
-
4. S. Hariri E. Dunne M. Saraiya E. Unger L. Markowitz 2011 Human Papillomavirus Chapter 5-1.
-
5. N.D. Christensen J. Dillner C. Eklund J.J. Carter G.C. Wipf C.A. Reed 1996 Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies Virology 223 174 184.
-
6. A.L. Combita A. Touze L. Bousarghin N.D. Christensen P. Coursaget 2002 Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses J Virol 76 6480 6486.
-
7. T.D. Culp C.M. Spatz C.A. Reed N.D. Christensen 2007 Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles Virology 361 435 446.
-
8. R.Z. Rizk N.D. Christensen K.M. Michael M. Muller P. Sehr T. Waterboer M. Pawlita 2008 Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types J Gen Virol 89 117 129.
-
9. M.G. Williams A.F. Howatson J.D. Almeida 1961 Morphological characterisation of the virus of the human common wart (verruca vulgaris) Nature 189 895 897.
-
10. R. Kirnbauer F. Booy N. Cheng D.R. Lowy J.T. Schiller 1992 Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc Natl Acad Sci USA 89 12180 12184.
-
11. N.D. Christensen C.A. Reed N.M. Cladel K. Hall G.S. Leiserowitz 1996 Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type specific epitopes on HPV-6 Virology 224 477 486.
-
12. D.M. Harper E.L. Franco C.M. Wheeler A.B. Moscicki B. Romanowski C.M. Roteli-Martins D. Jenkins A. Schuind S.A. Costa Clemens G. Dubin 2006 Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial Lancet 367 1247 1255.
-
13. N. Thones A. Herreiner L. Schadlich K. Piuko M. Muller 2008 A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response J Virol 82 5472 5485.
-
14. K. Heim N.D. Christensen R. Hoepfl B. Wartusch G. Pinzger A. Zeimet P. Baumgartner J.W. Kreider O. Dapunt 1995 Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups J Infect Dis 172 395 402.
-
15. H.D. Strickler A. Hildesheim R.P. Viscidi K.V. Shah B. Goebel J. Drummond D. Waters Y. Sun N.L. Hubbert S. Wacholder L.A. Brinton C.L. Han P.C. Nasca R. McClimens K. Turk V. Devairakkam S. Leitman C. Martin J.T. Schiller 1997 Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays J Clin Microbiol 35 1751 1756.
-
16. A. Wikstrom G.J. Van Doornum W.G. Quint J.T. Schiller J. Dillner 1995 Identification of human papillomavirus seroconversions J Gen Virol 76 529 539.
-
17. T. Giroglou M. Sapp C. Lane C. Fligge N.D. Christensen R.E. Streeck 2001 Immunological analyses of human papillomavirus capsids Vaccine 19 1783 1793.
-
18. X.S. Chen R.L. Garcea I. Goldberg G. Casini S.C. Harrison 2000 Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 Mol Cell 5 557 567.
-
19. S. Margaret R. Douglas I. Lowyb 2006 Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms.
-
20. S.Z. Xi L.M. Banks 1991 Baculo expression of the Human papilloma virus type 16 capsid proteins: detection of L1-L2 protein complexes J Gen Virol 72 2981 2988.
-
21. B. Zheng J. Wang H. Jiang 2001 Production of HPV 16 major capsid protein L1 with baculovirus expression system Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 15 314 316.
-
22. P. Le Cann P. Coursaget S. Iochmann A. Touze 1994 Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells FEMS Microbiol Lett 117 269 274.
-
23. G. Köhler C. Milstein 1975 Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495 497.
-
24. R. N. Hanumantha B. P. Baji L. Rajendra R. Sriraman Y.Y. Pang J.T. Schiller V.A. Srinivasan 2011 Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles Vaccine 29 7326 7334.
-
25. C.B. Buck D.V. Pastrana D.R. Lowy J.T. Schiller 2005 Generation of HPV pseudovirions using transfection and their use in neutralization assays Methods Mol Med 119 445 462.
-
26. D.V. Pastrana C.B. Buck Y.Y. Pang C.D. Thomson P.E. Castle P.C. Fitzgerald K.S. Kjaer D.R. Lowy J.T. Schiller 2004 Reactivity of human sera in a sensitive, high-throughput pseudovirusbased papillomavirus neutralization assay for HPV16 and HPV18 Virology 321 205 216.
-
27. M.D. Yeager M. Aste-Amezaga D.R. Brown M.M. Martin M.J. Shah J.C. Cook N.D. Christensen C. Ackerson R.S. Lowe J.F. Smith P. Keller K.U. Jansen 2000 Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies Virology 278 570 577.
-
28. R.B. Roden H.L. Greenstone R. Kirnbauer F.P. Booy J. Jessie D.R. Lowy J.T. Schiller 1996 In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype J Virol 70 5875 5883.
-
29. M.E. Hagensee N.H. Olson T.S. Baker D.A. Galloway 1994 Threedimensional structure of Vaccinia Virus produced Human papilloma virus Type 1 Capsids J Virol 68 7 4503 4505.
-
30. R.C. Rose W. Bonnez C. Da Rin D.J. McCance R.C. Reichman 1994 Serological differentiation of human papilloma virus types 11, 16 and 18 using Recombinant virus like particles J Gen Virol 75 2445 2449.
-
31. N.D. Christensen N. M. Cladel C. A. Reed L.R. Budgeon M.E. Embers D. M. Skulsky W.L. McClements S.W. Ludmerer K.U. Jansen 2001 Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types Virology 291 324 334.
-
32. N.D. Christensen R. Höpfl S.L. DiAngelo N.M. Cladel S.D. Patrick P.A. Welsh L.R. Budgeon C.A. Reed J.W. Kreider 1994 Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres J Gen Virol 75 2271 2276.
-
33. T.D. Culp C.M. Spatz C.A. Reed N.D. Christensen 2007 Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles Virology 361 435 446.
-
34. V.A. Olcese Y. Chen R. Schlegel H. Yuan 2004 Characterization of HPV16 L1 loop domains in the formation of a typespecific, conformational epitope BMC Microbiol 4 29.
-
35. S. Ressler R. Scheiden K. Dreier A. Laich E. Muller-Holzner H. Pircher D. Morandell L. Stein H.P. Viertler F.R. Santer A. Widschwendter J. Even P. Jansen-Durr C. Capesius W. Zwerschk 2007 High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma Clin Cancer Res 13 7067 7072.
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jul 2020 | 1 | 0 | 0 |
| Aug 2020 | 2 | 1 | 2 |
| Sep 2020 | 4 | 0 | 0 |
| Oct 2020 | 8 | 0 | 0 |
| Nov 2020 | 4 | 1 | 0 |
| Dec 2020 | 1 | 0 | 0 |
| Jan 2021 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory